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Background: To overcome antibiotic resistance in biofilms, enzymes aimed at biofilm dispersal are under investigation.
In the present study, applicability of an Aeromonas punctata derived depolymerase capable of degrading the capsular
polysaccharide (CPS) of Klebsiella pneumoniae, in disrupting its biofilm and increasing gentamicin efficacy against
biofilm was investigated.
Results: Intact biofilm of K. pneumoniae was recalcitrant to gentamicin due to lack of antibiotic penetration. On
the other hand, gentamicin could not act on disrupted biofilm cells due to their presence in clusters. However, when
depolymerase (20 units/ml) was used in combination with gentamicin (10 μg/ml), dispersal of CPS matrix by enzyme
facilitated gentamicin penetration across biofilm. This resulted in significant reduction (p < 0.05) in bacterial count in
intact and disrupted biofilms. Reduction in CPS after treatment with depolymerase was confirmed by confocal
microscopy and enzyme linked lectinosorbent assay. Furthermore, to substantiate our study, the efficacy of bacterial
depolymerase was compared with a phage borne depolymerase possessing similar application against K. pneumoniae.
Although both were used at same concentration i.e. 20 units/ml, but a higher efficacy of bacterial depolymerase
particularly against older biofilms was visibly clear over its phage counterpart. This could be explained due to high
substrate affinity (indicated by Km value) and high turnover number (indicated by Kcat value) of the bacterial
depolymerase (Km = 89.88 μM, Kcat = 285 s−1) over the phage derived one (Km = 150 μM, Kcat = 107 s−1).
Conclusion: Overall the study indicated that, the A. punctata derived depolymerase possesses antibiofilm
potential and improves gentamicin efficacy against K. pneumoniae. Moreover, it can serve as a potential substitute
to phage borne depolymerases for treating biofilms formed by K. pneumoniae.
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Biofilm is a community of microorganisms embedded in
a self produced polymeric matrix comprising of polysac-
charides, proteins, glycopeptides, nucleic acids and lipids
[1]. Currently, it is estimated that over 60 % of bacterial
infections and up to 80 % of chronic infections involve
microbial growth in biofilms [2]. K. pneumoniae is fre-
quently encountered in hospital-acquired urinary tract
infections (UTI), respiratory illnesses, burn wound infec-
tions, surgical site and catheter-related infections [3].
Mortality rates due to infections by this organism range* Correspondence: sanjaychhibber8@gmail.com
Department of Microbiology, Panjab University, Sector-14, Chandigarh
160014, India
© 2015 Bansal et al. This is an Open Access ar
(http://creativecommons.org/licenses/by/4.0),
provided the original work is properly credited
creativecommons.org/publicdomain/zero/1.0/between 25-60 % [4, 5]. Biofilm formation is a major
virulence trait used by K. pneumoniae to colonize the
human host [6]. The acidic CPS encasing the bacterium
provides resistance against dessication, phagocytosis,
killing by serum, induces cytotoxicity during infection of
lung epithelial cells and helps in biofilm formation at the
infection site [7, 8]. Recently, hypermucoviscous variants
of K. pneumoniae with increased virulence have emerged
in the Asia Pacific region and they are spreading across
the globe [9]. This dense, sticky mix of negatively
charged polysaccharides forms a three dimensional scaf-
fold which can range in thickness upto 50 μm [10, 11]. It
retards or blocks the penetration of antibiotics particularly
positively charged aminoglycosides, thus restricting their
access to the deeper layers [12]. This leads to sub-optimalticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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biofilm. Exposure of bacteria to sub-MIC concentrations
can further complicate the situation by enhancing CPS
production and increasing the emergence of resistant
strains. This has been observed in encapsulated isolates of
K. pneumoniae, Escherichia coli, P. aeruginosa [13]. Multi-
cellular nature of the polysaccharide also leads to creation
of nutrient starved zones in the biofilm interior as a result
of which some cells enter into a metabolically inactive
state leading to inability of antibiotics to act on them [14].
Chemical disinfectants like nitric oxide, metal chelators
like sodium citrate or tetrasodium-EDTA have been used
to disrupt biofilms in healthcare and industrial settings
but they leave toxic residues which have adverse effects
[15]. To overcome drug resistance in biofilms, efforts are
being directed towards developing anti-biofilm enzymes.
Polysaccharide-degrading enzymes like α-amylases, dis-
persin B (DspB), alginate lyases, deoxyribonucleases
(DNAses), phage depolymerases have been successfully
used for preventing biofilm formation or disrupting the
biofilms of S. aureus, S. epidermidis, E. coli and P. aeru-
ginosa, K. pneumoniae [16]. Such enzymes offer several
advantages: firstly, they are safe and have no side effects.
Secondly, they do not require actively growing cells for
their action and can act with the same frequency on
metabolically active as well as inert cells [17, 18].
Thirdly, they are not directly bactericidal so they do not
allow generation of resistant mutants. Although, the po-
tential of phage depolymerases for disrupting the bio-
films of K. pneumoniae and mediating the entry of
antimicrobials has been recognized but, no report is
available describing the use of enzymes from unrelated
bacterial genera for disrupting K. pneumoniae polysac-
charide in biofilms. The present study was undertaken
to study the potential of a Aeromonas punctata derived
depolymerase directed against K2 CPS of K. pneumo-
niae in disrupting the biofilms formed by this pathogen
and improving its susceptibility to antibiotic. The bio-
film disruption efficacy of A. punctata derived depoly-
merase with a previously characterized phage borne
depolymerase against K. pneumoniae B5055 was also
compared.Methods
Bacterial strain, antibiotic
K. pneumoniae B5055 (O1:K2) [MTCC 5832] obtained
from Dr. M. Trautman, Department of Medical
Microbiology and Hygiene, University of Ulm, Germany
was used in the present study. Maintenance of bacteria on
nutrient agar slants and preparation of gentamicin
(Himedia, India) was done as described previously [19].
Gentamicin was used at a final concentration of 10 μg/
ml throughout the study.Enzyme
Aeromonas punctata (Accession no: KF158411) was cul-
tivated in a statistically optimized media as standardized
in our laboratory [20]. Cell free supernatant containing
bacterial depolymerase directed against K2 CPS of K.
pneumoniae B5055 was obtained. The enzyme was puri-
fied by anion exchange (DEAE) followed by gel filtration
chromatography (Sephadex G100) [20]. CPS extracted
from K. pneumoniae B5055 following the method of Han-
lon et al. [21] was used as substrate for determining depo-
lymerase activity by the method of Miller [22]. One unit of
enzyme activity was defined as the micromoles of reducing
sugars released ml−1 min−1 when the reaction was carried
out at 37 °C and pH 7 for 60 min. Temperature and pH
optima and stability for bacterial depolymerase are
depicted in Additional file 1: Figure S1. Enzyme kinetics
was determined for the purified protein using various sub-
strate concentrations and Km, Vmax, kcat, kcat/Km were cal-
culated for the enzyme (Additional file 1: Figure S2).
For all experiments involving the use of A. punctata
derived bacterial depolymerase for various applications,
a previously characterized phage depolymerase capable
of acting on K2 CPS of K. pneumoniae B5055 was also
used. Phage depolymerase was extracted from a previ-
ously characterized, K. pneumoniae specific phage
‘KPO1K2’ (Verma et al. [23]) following the acid denatur-
ation method of Reiger et al. [24]. Its purification and
quantification was carried out in a similar manner as
done for bacterial depolymerase. Both the enzymes were
used at a concentration of 20 depolymerase units. All
experiments involving the use of both the biological
moieties were performed at 37 °C and pH 7 which was
the temperature and pH optima for both the enzymes.
The characteristics of phage depolymerase are depicted
in Additional file 1: Figure S3 and Table S1.
Capsule staining
Overnight culture of K. pneumoniae B5055 grown in nutri-
ent broth at 37 °C was taken, cells were washed with PBS
and diluted to obtain a count of 106 CFU/ml. Bacterial
depolymerase was added to a final concentration of 20
units/ml and cells were incubated for 30 min at 37 °C. Cells
suspended in PBS acted as control. Both the bacterial sus-
pensions were taken on a clean glass slides, mixed with a
drop of safranin and a smear was made. It was then coun-
terstained with crystal violet for 1 min, washed and exam-
ined under a light microscope.
Penetration of gentamicin through intact biofilm
Penetration of gentamicin through biofilm formed by K.
pneumoniae was determined according to the method of
Anderl et al. [25] with modifications. Overnight culture
of K. pneumoniae grown in nutrient broth was taken,
cells were washed and diluted to obtain a bacterial count
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to seed 25 mm polycarbonate discs (0.4 μm, Millipore)
placed on nutrient agar plates. The drop was allowed to
dry and plates were incubated at 37 °C. On days 1, 3, 5,
7, membrane biofilms were transferred to fresh nutrient
agar plates containing a fresh lawn of E. coli ATCC 25922
(standard strain of E. coli used for quality control). On top
of biofilm formed on 25 mm polycarbonate membrane,
sterile 13 mm membrane (0.4 μm, Millipore) was carefully
placed, such that the underlying biofilm was not disturbed.
Sterile gentamicin disc (10 μg/ml, Hi-media) was then
gently kept on the top of it and plates were incubated at
37 °C. Next day zone of clearance was measured on nutri-
ent agar plate containing a lawn of E. coli ATCC 25922
[25]. Control assembly in which gentamicin disc was kept
over sterile polycarbonate disc devoid of biofilm was also
put alongwith the test. The zone of growth inhibition in
control assembly was taken as 100 % penetration and used
for determining the percentage penetration/retardation of
antibiotic through biofilm. Experiment was repeated thrice
in triplicates.
Antibiotic susceptibility of planktonic, intact and
disrupted biofilm cells
Intact biofilm was established in 96 well microtiter plate
following the method described by Bedi et al. [26].
Briefly, 100 μl of nutrient broth and 100 μl of bacterial
culture equivalent to 108 CFU/ml (OD600 = 0.3) of K.
pneumoniae was added to the wells and incubated over-
night at 37 °C. After 24 h, supernatant was aspirated
from the wells (n = 6) and 3 washings were given with
sterile 0.85 % NaCl. Thereafter, gentamicin (10 μg/ml)
was added to wells (n = 6). Biofilm in wells (n = 3) was
disrupted using sterile toothpick according to the
method described by El-Azizi et al. [27]. After an incu-
bation of 6 h, wells with disrupted biofilm were aspirated
(n = 3) while those with intact biofilm (n = 3) were
scraped and added to sterile eppendorfs. The bacteria
were vortexed and appropriately diluted in sterile 0.85 %
NaCl. Bacterial count was estimated by plating the sam-
ples on nutrient agar plates. Percentage viability was cal-
culated as ratio of cells in treated wells to cells in
untreated, control wells multiplied by 100. In addition,
to determination of viable count, the intact and dis-
rupted biofilm were viewed under a fluorescent micro-
scope (B2A filter set, Nikon, 40 X) after staining with
Live/Dead staining Kit (Invitrogen) for 15 min. [Live/
Dead staining kit contains 3.34 mM Syto 9 (stains live
cells green) and 20 mM Propidium iodide (stains dead
cells red)].
Simultaneously, antibiotic susceptibility of planktonic
cells was determined by growing bacteria in 1 ml nutri-
ent broth. After an incubation of 24 h, bacterial suspen-
sion was centrifuged, washed twice with 0.85 % NaCland suspended in 1 ml fresh nutrient broth with genta-
micin (10 μg/ml). After 6 h of incubation, bacteria were
stained and percentage viability was determined by vi-
able count.
Treatment of intact and disrupted biofilm with
depolymerase and antibiotic alone as well as in
combination
Biofilm was formed in microtiter titer plate as described
in section Antibiotic susceptibility of planktonic, intact
and disrupted biofilm cells. On each day, supernatant
was aspirated from all the wells and replaced with fresh
nutrient broth. Three washings were given with sterile
0.85 % NaCl to a certain number of wells (n = 30). They
were treated with various agents [gentamicin (10 μg/
ml)/phage depolymerase (20 units/ml)/bacterial depoly-
merase (20 units/ml)/gentamicin + phage depolymerase/
gentamicin + bacterial depolymerase, n = 6 each]. Biofilm
in certain number of wells (n = 15) was disrupted using
sterile toothpick by the method of El-Azizi et al. [27].
After an incubation of 6 h, wells with disrupted (n = 15)
and intact biofilm (n = 15) were processed as described
in section Antibiotic susceptibility of planktonic, intact
and disrupted biofilm cells and viable count determined
by plating the samples on nutrient agar plates. Biofilm
was allowed to grow in different wells till 7 days. On each
day, a set of 3 wells was processed for control, untreated
intact and disrupted biofilm and the experiment was re-
peated thrice. The data was log transformed and for each
time point mean of all replicate values was taken.
Confocal laser-scanning microscopy (CLSM) of biofilm
Sterile plastic cover slips (18 x 18 mm) placed in 12 well
mutidishes (Nunc) were inoculated with 1.5 ml culture
of K. pneumoniae (1 × 108 CFU/ml) and 1.5 ml nutrient
broth and incubated at 37 °C. Each day, spent medium
was removed and replaced with fresh nutrient broth. On
3rd and 7th day, the cover slips were washed thrice with
0.85 % NaCl, followed by treatment with 20 units/ml of
either phage or bacterial depolymerase for 1 h at 37 °C.
Thereafter, the cover slips with untreated and treated
biofilms were stained with 300 mg/ml calcofluor white
(Sigma) [calcofluor white binds to the sugar residues in
the biofilm polysaccharide and stains them blue] and
0.1 % Syto 62 (Molecular Probes) [Syto 62, a nucleic acid
staining dye stains the bacterial cells red] for 15 min each.
These were then examined under a Inverted Olympus
Fluoview CLSM (FV 1000, Olympus America Inc. NY,
USA). All images were obtained with a 20X lens. Multiple
images were collected for each set of experimental condi-
tions; a representative image is presented for each group
in the results section. Image analysis was done using z-
series image stacks from four randomly chosen spots of
each biofilm. The ratio of cell biomass to polysaccharide
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density with integrated blue fluorescence density using
ImageJ version 1.46r [57].
Quantitative estimation of CPS by enzyme linked
lectinosorbent assay (ELLA)
CPS was quantified in the untreated/treated biofilm fol-
lowing the method of Strathmann et al. [28]. Briefly, intact
biofilm was grown in microtiter plate and appropriately
treated with phage/bacterial depolymerase as described in
section Treatment of intact and disrupted biofilm with
depolymerase and antibiotic alone as well as in combin-
ation. The biofilm was subsequently washed with phos-
phate buffer saline (PBS, 0.1 M, pH 7.2) twice and fixed
with 200 μl of 95 % ethanol for 15 min. 100 μl of blocking
solution [1 % w/v BSA in PBST (PBS plus 0.05 % Tween
20)] was added to the wells and incubated for 1 h at 37 °C.
It was then pipetted out and 100 μl ConA–HRP (10 mg/
ml) in 1 % BSA in PBST was added to wells. The microti-
ter plate was incubated for 30 min at 37 °C. Wells were
washed thrice for 5 min with PBST. 100 μl of TMB sub-
strate (BD Biosciences) was added and microtiter plate
was incubated for 30 min at 37 °C. Reaction was stopped
by adding 50 μl of 2 N H2SO4. CPS content (μg/ml) was
measured in terms of peroxidase activity by taking absorb-
ance at 450 nm. Experiment was performed in triplicate
and repeated thrice.
Statistical analysis
The effect of different treatments on biofilm was evalu-
ated by applying one-way ANOVA and P < 0.05 was con-
sidered significant. Data was analyzed using SPSS 16.0.
Results
The present study was conducted to evaluate the poten-
tial of A. punctata derived depolymerase to decapsulate
K. pneumoniae B5055 and improve gentamicin efficacy
against its biofilms.
Enzyme kinetics for bacterial depolymerase
Bacterial depolymerase exhibited simple hyperbolic
Michaelis-Menten kinetics. Lineweaver Burk plot was
constructed and values depicting its kinetics i.e. Km,
Vmax, kcat and kcat/Km were calculated as 89.88 μM,
43.35 μmol min−1, 285 s−1 and 3.17 s−1.μM−1 respectively
(Additional file 1: Figure S2). Enzyme kinetics was also deter-
mined for the phage depolymerase and the values for Km,
Vmax, kcat and kcat/Km are 150 μM, 20 μmol min
−1, 107 s−1
and 0.71 μM−1 respectively. (Additional file 1: Table S1).
Microscopic examination of bacteria after capsule
staining
A clear hollow depicting capsule was visible surrounding
the untreated bacteria (Fig. 1a). On the other hand,depolymerase treated bacteria were devoid of any cap-
sule (Fig. 1b).
Penetration of gentamicin
Percentage retardation of gentamicin through colony
biofilm of K. pneumoniae established on 25 mm polycar-
bonate disc was studied. As shown in Table 1, in com-
parison to inhibition zone observed on plates having
membrane with no biofilm, a significant decrease in the
diameter of inhibition zone (p < 0.05) was observed on
plates in which membrane with colony biofilm was
placed. Percentage antibiotic retardation increased with
an increase in biofilm age. Retardation of gentamicin
was 26.66 % for 1 day old biofilm. It progressively in-
creased to 86.66 % for 7 day old biofilm (Table 1).
Antibiotic susceptibility of planktonic, intact and
disrupted biofilm cells
Percentage viability of planktonic cells, intact and dis-
rupted biofilm cells treated with gentamicin was 10 %,
100 % and 99.6 % respectively. Visualization of gentami-
cin treated cells under a fluorescent microscope indi-
cated resistance of intact biofilm as a great number of
green coloured viable cells (Syto 9 stained; Fig. 2b) were
observed. The disrupted biofilm also consisted of large
clumps of mostly viable, green cells (Fig. 2c). In contrast,
all planktonic cells were dead as they acquired red color
(PI stained, Fig. 2a). This indicated that, the disrupted bio-
film cells were more or less similar in their antibiotic sus-
ceptibility pattern to bacteria in a intact biofilm.
Effect of depolymerase and antibiotic alone as well as in
combination on intact biofilm
The efficacy of depolymerase on gentamicin penetration
and bacterial count was studied in intact biofilm. No sig-
nificant difference (p > 0.05) was observed in average
bacterial count of gentamicin treated biofilm and un-
treated biofilm (Fig. 3). This indicated the inability of
antibiotic alone to tackle biofilm. When bacterial depoly-
merase was used alone, an average reduction of 3.261 ±
0.14 log in bacterial count was observed in comparison
to untreated biofilm (Fig. 3). In contrast, an average re-
duction of 2.242 ± 0.21 log was observed after treatment
with phage depolymerase alone (Fig. 3). Treatment with
gentamicin and phage or bacterial depolymerase resulted
in significant reduction (p < 0.05) of 4.259 ± 0.34 log and
5.373 ± 0.18 log respectively in bacterial counts of young
biofilm (till 4th day) (Fig. 3). 5th day onwards a significant
reduction of 3.506 ± 0.16 log (p < 0.05) was observed in
biofilm treated with bacterial depolymerase and genta-
micin. In contrast, an insignificant reduction (p > 0.05)
was observed in biofilm treated with phage depolymer-
ase and gentamicin (Fig. 3).
Fig. 1 Microscopic appearance of K. pneumoniae B5055: (a) encapsulated untreated bacteria (b) depolymerase treated bacteria
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combination on disrupted biofilm
No significant difference (p > 0.05) was observed in aver-
age bacterial count of gentamicin treated and untreated
disrupted biofilm (Fig. 4). Therefore, disrupted biofilm
was treated with phage/bacterial depolymerase alone as
well as in combination with gentamicin. In comparison
to untreated biofilm, no significant reduction (p > 0.05)
was observed in the count of disrupted cells (Fig. 4) after
treatment with phage or bacterial depolymerase alone.
However, on negative staining, bacteria were found to be
devoid of capsule compared to untreated cells (data not
presented). Treatment with either of the enzyme in com-
bination with gentamicin resulted in complete eradica-
tion of 1 day old biofilm (Fig. 4). 2nd day onwards a
significant reduction (p < 0.05) of 6.679 ± 0.21 log in the
average bacterial count was observed after treatment
with bacterial depolymerase and gentamicin. In contrast,
an average reduction of 5.121 ± 0.18 log was observed in
biofilm treated with phage depolymerase and gentamicin
in combination (Fig. 4).
Qualitative analysis of CPS in biofilm
To determine the ability of bacterial depolymerase in
dispersing the polysaccharide matrix enmeshing the bac-
terial cells, untreated/treated biofilms were visualized
under a confocal microscope. Cover slips with biofilm
treated with phage depolymerase were also put up sim-
ultaneously. In images taken using CLSM, blue regionsTable 1 Penetration of gentamicin (10 μg/ml) through biofilm of K.
Biofilm age (Days) Inhibition zones (mm) observed following penetra
Membrane with no biofilm
1 15 ± 0.06
3 15 ± 0.08
5 15 ± 0.12
7 15 ± 0.05
The zone of growth inhibition observed on plates with discs having no biofilms wa
retardation of gentamicin through biofilms. Data is presented as mean ± SD. The exrepresent polysaccharide matrix while red regions indi-
cate zones containing cells of K. pneumoniae (Fig. 5).
Purple regions resulted from overlap of red and blue
pixels; representing bacterial cells embedded in polysac-
charide. With an increase in biofilm age, an increase in
biofilm bacterial mass (red) as well as dense matrix
(blue) was observed in untreated biofilm (Fig. 5a and b).
This indicated high bacterial density and tightly packed
regions of heterogeneously distributed dense polysac-
charide in the form of tower or mushroom-shaped clusters
in untreated biofilm. A significant change was observed in
the enzyme treated biofilm. In comparison to young biofilm
treated with phage depolymerase (Fig. 5c), biofilm treated
with bacterial depolymerase showed significant decrease in
polysaccharide matrix (indicated by blue regions) as well as
in surface coverage by bacterial cells (indicated by red re-
gions) (Fig. 5e). In young biofilms, ratio of cell biomass to
polysaccharide matrix (integrated red fluorescence density/
integrated blue fluorescence density) after bacterial depoly-
merase treatment was 2.95 U whereas after phage depoly-
merase treatment it was 1.14 U. In phage depolymerase
treated old biofilm, polysaccharide was sparsely distributed
in certain areas (Fig. 5d) whereas in bacterial depolymerase
treated old biofilm cloud like structure of polysaccharide
was rarely present (Fig. 5f). Ratio of cell biomass to
polysaccharide in 7 day old biofilm treated with bacterial
depolymerase (1.51 U) was significantly higher (p < 0.01)
than that observed after phage depolymerase treatment
(0.58 U) or in untreated biofilm (0.34 U). No significantpneumoniae B5055
tion of gentamicin through disc placed on % Retardation
Membrane with colony biofilm
11 ± 0.14 26.66 ± 0.17
7 ± 0.18 53.33 ± 0.18
3 ± 0.12 80.06 ± 0.15
2 ± 0.13 86.66 ± 0.20
s taken as 100 % penetration and used to determine the percentage
periment was performed thrice in triplicates
Fig. 2 Planktonic cells (a) Intact biofilm (b) and Disrupted biofilm (c) incubated for 6 h with gentamicin (10 μg/ml), stained with LIVE/DEAD
BacLight bacterial viability kit and visualized under a fluorescent microscope. Magnification: 40X, Scale:20 μm
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blue fluorescence in phage depolymerase treated (0.58 U)
or untreated (0.34 U), 7 day old biofilm.Quantification of CPS in treated/untreated biofilms by
ELLA
ELLA involving measurement of peroxidase activity after
binding of horse radish peroxidase (HRP) labeled lectin
(concanavalin A) to sugar residues in polysaccharide was
used for quantification of polysaccharide content in bio-
film before and after treatment. A significant difference
(p < 0.05) was observed in the average polysaccharide
content (μg/ml) of untreated (1.41 ± 0.26) and bacterial
depolymerase treated biofilm (0.45 ± 0.17) (Table 2). In
contrast, no significant difference in average polysac-
charide content was observed in untreated biofilm
(1.41 ± 0.26) and biofilm treated with phage depolymerase
(0.90 ± 0.25) (Table 2).Fig. 3 Bacterial count (Log10CFU/ml) following treatment of intact biofilm of K.
bacterial enzyme (20 units/ml) alone as well as in combination. The experiment
(gentamicin treated vs untreated), $p < 0.05 (bacterial/phage enzyme treated
gentamicin treated vs untreated)]. Denatured bacterial/phage depolymerase h
But no effect on CPS content was observedDiscussion
CPS forms thick bundles of fibrillous structures that
cover the entire surface of Klebsiella [7]. Because of the
inherent tolerance of biofilm to antibiotics, there is a
growing need for developing strategies for tackling bio-
films [29, 30]. The future of biofilm control lies in using
microbes which produce antifouling enzymes [32]. Amy-
lases, proteases, alginate lyases, dispersin, polyglutamic
acid depolymerases have been widely accepted for dis-
rupting the polysaccharides of P. aeruginosa, S. aureus,
Bacillus spp. etc. [31]. Various commercially available
proteases and polysaccharide degrading enzymes of bac-
terial and fungal origin, such as glucose oxidase (Novo
Nordisk), Lactoperoxidase (Sigma), Pectinex Ultra SP
(Novo Nordisk), Mutanase (Novo Nordisk), Dextranase
(Novo Nordisk), Subtilisin A (Novo Nordisk) have been
used against biofilm formed by Streptococcus mutans,
Staphylococcus and Pseudomonas spp. in various envir-
onmental, clinical and industrial settings [32]. In ourpneumoniae grown in microtiter plate, with gentamicin (10 μg/ml)/phage/
was performed thrice in triplicate. Error bars = ± SD; n= 3 [*p> 0.05
vs untreated), #p < 0.05 (bacterial enzyme + gentamicin/phage enzyme+
eated at 75 °C for 10 min were used as controls for biofilm treatment.
Fig. 4 Bacterial count (Log10CFU/ml) following treatment of disrupted biofilm of K. pneumoniae grown in microtiter plate, with gentamicin (10 μg/ml)/
phage/bacterial enzyme (20 units/ml) alone as well as in combination. The experiment was performed thrice in triplicate. Error bars = ± SD; n= 3. [*p> 0.05
(gentamicin/bacterial enzyme/phage enzyme treated vs untreated), #p< 0.05 (bacterial enzyme + gentamicin/phage enzyme + gentamicin treated vs
untreated)]. Denatured bacterial/phage depolymerase heated at 75 °C for 10 min were used as controls for biofilm treatment. But no effect on CPS
content was observed
Fig. 5 3-D reconstruction of 3 and 7 day old biofilm after staining with calcofluor white and Syto 62 (a) 3 day untreated biofilm (b) 7 day
untreated biofilm (c) 3 day biofilm treated with phage depolymerase (d) 7 day biofilm treated with phage depolymerase (e) 3 day biofilm treated
with bacterial depolymerase (f) 7 day biofilm treated with bacterial depolymerase. Both the enzymes were used at 20 units/ml. (Magnification
200X). [3D]: 3 day old biofilm, [7D]: 7 day old biofilm, Scale: 10 μm
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Table 2 CPS content (μg/ml) following treatment of K. pneumoniae biofilm of different days with phage/bacterial depolymerase
(20 units/ml each)
Biofilm age CPS content (μg/ml)
Days Untreated Phage enzyme treated* Bacterial enzyme treated#
1 0.989 ± 0.15 0.639 ± 0.22 0.279 ± 0.18
3 1.082 ± 0.24 0.846 ± 0.36 0.357 ± 0.17
5 1.589 ± 0.09 0.978 ± 0.24 0.511 ± 0.15
7 2.014 ± 0.35 1.168 ± 0.28 0.656 ± 0.19
Data is presented as mean ± SD (n = 3). [*p > 0.05 (average CPS content in phage depolymerase treated vs untreated biofilm), #p < 0.05 (average CPS content in
bacterial depolymerase treated vs untreated biofilm)]. Denatured bacterial/phage depolymerase heated at 75 °C for 10 min were used as controls for biofilm
treatment. But no effect on CPS content was observed
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has been shown to improve gentamicin efficacy during K.
pneumoniae induced murine infection [19]. Thus, the
potential of this depolymerase found to be extensively hom-
ologous to protein of unknown function from A. cavaie
Ae398 [20], in mediating dispersal of biofilm formed by K.
pneumoniae and improving gentamicin action was evalu-
ated in this study.
Decapsulation of K. pneumoniae B5055 after treatment
with A. punctata derived depolymerase is depicted in
Fig. 1. Unlike antibacterial enzymes like endolysins, lysos-
taphin, lysozyme etc., depolymerase renders the bacterium
susceptible to various antimicrobial agents due to diges-
tion of outer CPS [33]. Aminoglycosides have been widely
used for inhibiting/restricting the growth of members of
enterobactericiae family. Thus, gentamicin was selected
for use along with A. punctata derived depolymerase. It
was used at 10 μg/ml throughout the study, as it is the
clinical achievable concentration and optimal concentra-
tion approved by CLSI guidelines [34]. Resistance of intact
biofilm to gentamicin may be due to the binding of posi-
tively charged aminoglycoside to negatively charged bio-
film matrix. This has been reported by earlier workers, as
tobramycin exhibited a limited or delayed penetration
across biofilm of P. aeruginosa [35, 36]. Thus, a significant
decrease in the penetration of gentamicin with progres-
sion in biofilm age observed in this study, was possibly
due to binding of gentamicin to the biofilm matrix. Sub-
MIC levels of antibiotic thus reaching the biofilm interior
may induce matrix synthesis and biofilm formation as re-
ported for P. aeruginosa and Escherichia coli [29]. Re-
peated antibiotic dosing also offers no advantage in such
cases as it causes saturation of binding sites rather than
improving penetration across the biofilm [37, 38]. Thus in
this study, young and old biofilm of K. pneumoniae were
treated with bacterial depolymerase. Although bacterial
depolymerase when used alone was not directly bacteri-
cidal, a reduction in bacterial count of intact biofilm was
observed. This might be due to enzyme catalyzed cleavage
of the polysaccharide which caused a removal of the
loosely bound, un-encapsulated cells. Earlier studies have
reported the use of Dispersin B, ‘a biofilm releasingenzyme’ synergistically with various antimicrobials for the
removal of biofilm formed by S. aureus, S. epidermidis
and E. coli [39–41]. Therefore, when bacterial depolymer-
ase was used along with gentamicin, degradation of nega-
tively charged polysaccharide matrix enmeshing bacteria
in a biofilm facilitated the transport of positively charged
gentamicin across the biofilm. It ensured rapid killing of
bacteria present in deeper layers and prevented exposure
of bacteria to sub-MIC concentrations of antibiotic as
has been reported earlier [42]. Increase in biofilm
matrix with an increase in biofilm age which contrib-
uted towards inability of gentamicin to penetrate was
confirmed by viewing the biofilms by CLSM. The degrad-
ation of polysaccharide after treatment with bacterial
depolymerase which led to dispersal of loosely bound cells
and killing of deep seated bacterial cells by gentamicin
was also confirmed through CLSM and ELLA.
Biofilm disruption occurs during its dispersal, due to
fluid infusion through them or due to removal of im-
planted biomaterials like catheters, stents, cardiac pace-
makers, endotracheal tubes, joint prostheses, peritoneal
dialysis catheters, cerebrospinal fluid shunts etc. Shed
bacteria can enter into circulation and cause infections
like pneumonia, septicemia and secondary infections es-
pecially in immunocompromised individuals [43]. They
can also readhere and initiate biofilm formation else-
where. Stewart and Costerton [44] have reported that
antibiotics might kill the free floating bacteria shed from
a biofilm. Contrasting results were obtained in our study
whereby significant recalcitrance of disrupted biofilm
cells to gentamicin was observed. This might be due to the
presence of disrupted biofilm cells in clusters. Inability of
vancomycin and linezolid to combat disrupted biofilm of
methicillin resistant S. aureus (MRSA) and methicillin sus-
ceptible S. aureus (MSSA) at concentrations 1000 times
higher than their MICs has also been reported by El-Azizi
et al. [27]. Bacterial depolymerase when used in combin-
ation with gentamicin caused significant reduction in the
count of disrupted cells due to their release from cluster.
Throughout this study, a previously characterized
phage borne depolymerase capable of degrading the CPS
of K. pneumoniae B5055 was used alongwith bacterial
Bansal et al. BMC Microbiology  (2015) 15:119 Page 9 of 10depolymerase for biofilm treatment. Even though both
the biological entities were used at 20 units ml−1, but a
better efficacy of bacterial depolymerase over its phage
counterpart was visibly clear. During biofilm treatment,
phage depolymerase caused ineffective dissolution of
polysaccharide especially in older biofilm. Thus, reduc-
tion in bacterial count in biofilms treated with phage
depolymerase was ~2 log less in comparison to biofilm
treated with bacterial depolymerase. Similarly, polysac-
charide content after bacterial depolymerase treatment
was significantly less in comparison to that observed in
biofilm after phage depolymerase treatment. Reason for
this anomaly lies in the enzyme kinetics of both the en-
zymes. Interestingly, a high affinity of the bacterial depo-
lymerase towards its substrate (indicated by its lower Km
value = 89.88 μM) over that of phage depolymerase (Km
value = 150 μM) and its higher efficiency in liberating re-
ducing sugars [indicated by a higher turnover number
(kcat = 285 s
−1)] over phage depolymerase (kcat =107 s
−1)
was possibly a reason for its higher efficacy than the
phage depolymerase (Kinetics of phage depolymerase:
Additional file 1: Table S1). Jun et al. [45] have reported
a phage endolysin ‘SAL-1’, to possess better efficacy than
endolysin ‘LysK’ due to alterations in amino acid resi-
dues in catalytic domain. This is the first comparative
study on two biological entities capable of degrading the
CPS of a gram negative bacterium. The enzyme of bac-
terial origin was found to show better efficacy over its
phage derived counterpart. It is suggested that these bio-
logical entities should be further explored for valuable
insights into this interesting phenomena.
Conclusion
In recent times, antimicrobial drug development is in-
creasingly lagging behind the evolution of antibiotic resist-
ance. Considering the degree of virulence possessed by K1
or K2 CPS containing K. pneumoniae strains [46] newer
antibiofilm therapeutic paradigms are required. The
potential of phage borne depolymerase in degrading the
biofilm polysaccharide and allowing the phage or other
antimicrobials to reach the bacterial cell surface has
been widely demonstrated [47–50]. But, obtaining large
amounts of phage depolymerases from phage lysates is
difficult [33, 51, 52]. Moreover, chances of isolating a
natural phage that is specific for a bacteria to be tar-
geted and having the ability to express a relevant poly-
saccharide degrading enzyme are low [53]. A strategy of
engineering bacteria specific phages to express effective
polysaccharide degrading enzymes has been looked upon
[34]. Use of genetically modified phages which help in
overcoming antibiotic resistance [54] or which efficiently
kill but simultaneously minimize endotoxin release from
the pathogen [55, 56] is also being tried. But, instead of
adopting a tedious approach, an enzyme derived fromnaturally occurring unrelated bacterial genera was used in
this study. Such enzymes do not allow generation of resist-
ant mutants, do not involve bacterial lysis and subsequent
release of proinflammatory mediators, do not require ac-
tively growing cells to exert their action and serve as ad-
juncts to improve antibiotic action. Promising results
obtained with bacterial depolymerase and its better effi-
cacy in comparison to phage depolymerase warrant its fur-
ther evaluation in in vivo studies so that it can be readily
incorporated in prophylactic/therapeutic regimes.
Additional file
Additional file 1: Characteristics of bacterial and phage
depolymerase Figure S1. Determination of optimum temperature (a)
and temperature stability (b) of bacterial depolymerase. Determination of
optimum pH (c) and pH stability (d) of bacterial depolymerase. Figure S2.
Line-weaver Burk plot depicting the kinetics of bacterial depolymerase.
Km=89.88 μM, Vmax=43.35 μmole/min, Kcat=285 s-1, Kcat/Km= 3.17 s-1.μM-1.
Figure S3. Determination of optimum temperature (a) and temperature sta-
bility (b) of phage ‘KPO1K2’ derived depolymerase. Determination of
optimum pH (c) and pH stability (d) of phage ‘KPO1K2’ derived depolymer-
ase. Table S1. Kinetics of phage depolymerase.
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